Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $35.0M (80.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 11, 2025 | Mar 28, 2024 | Mar 2, 2023 | Mar 1, 2022 |
| Revenue | $43.8M | $6.34M | – | – | – |
| Operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M |
| Research and development | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M |
| Selling, general and administrative | $29.7M | $24.8M | $27.0M | $29.9M | $23.9M |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| EPS, basic | $-4.19 | $-1.09 | $-2.78 | $-3.22 | $-13.52 |
| EPS, diluted | $-4.19 | $-1.09 | $-2.78 | $-3.22 | $-13.52 |
| Weighted shares, basic | 8.36M | 53.5M | 27.5M | 27.4M | 5.61M |
| Margins and growth | |||||
| Operating margin | -95.9% | -954.9% | – | – | – |
| Net margin | -80.1% | -918.0% | – | – | – |
| Revenue growth, year over year | +589.9% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 11, 2025 | Mar 28, 2024 | Mar 2, 2023 | Mar 1, 2022 |
| Cash and equivalents | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M |
| Total current assets | $145.0M | $60.2M | $48.1M | $124.5M | $202.5M |
| Property, plant and equipment | $3.89M | $4.47M | $5.94M | $7.25M | $7.62M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Accounts payable | $3.17M | $2.57M | $1.05M | $3.13M | $3.14M |
| Total current liabilities | $56.3M | $27.3M | $16.0M | $21.1M | $12.8M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Shareholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Mar 11, 2025 | Mar 28, 2024 | Mar 2, 2023 | Mar 1, 2022 |
| Operating cash flow | -$4.99M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Capital expenditures | $518.0K | $36.0K | $486.0K | $1.87M | $1.10M |
| Free cash flow | -$5.51M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Depreciation and amortization | $1.54M | $1.64M | $1.90M | $1.85M | $1.50M |
| Stock-based compensation | $6.94M | $6.43M | $7.38M | $8.42M | $4.96M |
| Investing cash flow | -$518.0K | -$36.0K | -$486.0K | -$1.87M | -$1.10M |
| Financing cash flow | $87.8M | $29.2M | -$6.55M | -$69.0K | $260.7M |
| Net change in cash | $82.3M | $10.8M | -$75.7M | -$77.7M | $178.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15.9% | 101.4% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 7.06M | −86.5% | SEC |
| Mar 18, 2026 | 5.78M | −88.8% | SEC |
| Nov 11, 2025 | 52.5M | +19.4% | SEC |
| Aug 8, 2025 | 51.8M | +17.9% | SEC |
| May 5, 2025 | 51.8M | +40.3% | SEC |
| Mar 3, 2025 | 51.8M | +50.2% | SEC |
| Nov 1, 2024 | 44.0M | +59.6% | SEC |
| Aug 1, 2024 | 44.0M | +59.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-14 in Q1 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.